Your browser doesn't support javascript.
loading
miR-198 inhibits the progression of renal cell carcinoma by targeting BIRC5.
Yuan, Chao; Su, Zhenhong; Liao, Shengjie; Li, Duanzhuo; Zhou, Zhiwen; Wang, Yawen; Quan, Mingchun; Zeng, Lingling; Lv, Cai; Shen, Chenyi; Gong, Weida; Wu, Jianfeng; Chen, Xiaogang; Hu, Wenbing; Lv, Xu; Si, Wenxia; Yu, Xin.
Afiliação
  • Yuan C; Hubei Key Laboratory for Kidney Disease Pathogenesis and Intervention, Hubei Polytechnic University School of Medicine, Xialu District guilin north, road no. 16, Huangshi, 435003, Hubei, China.
  • Su Z; Hubei Key Laboratory for Kidney Disease Pathogenesis and Intervention, Hubei Polytechnic University School of Medicine, Xialu District guilin north, road no. 16, Huangshi, 435003, Hubei, China.
  • Liao S; Hubei Key Laboratory for Kidney Disease Pathogenesis and Intervention, Hubei Polytechnic University School of Medicine, Xialu District guilin north, road no. 16, Huangshi, 435003, Hubei, China.
  • Li D; Hubei Key Laboratory for Kidney Disease Pathogenesis and Intervention, Hubei Polytechnic University School of Medicine, Xialu District guilin north, road no. 16, Huangshi, 435003, Hubei, China.
  • Zhou Z; Hubei Key Laboratory for Kidney Disease Pathogenesis and Intervention, Hubei Polytechnic University School of Medicine, Xialu District guilin north, road no. 16, Huangshi, 435003, Hubei, China.
  • Wang Y; Hubei Key Laboratory for Kidney Disease Pathogenesis and Intervention, Hubei Polytechnic University School of Medicine, Xialu District guilin north, road no. 16, Huangshi, 435003, Hubei, China.
  • Quan M; Hubei Key Laboratory for Kidney Disease Pathogenesis and Intervention, Hubei Polytechnic University School of Medicine, Xialu District guilin north, road no. 16, Huangshi, 435003, Hubei, China.
  • Zeng L; Hubei Key Laboratory for Kidney Disease Pathogenesis and Intervention, Hubei Polytechnic University School of Medicine, Xialu District guilin north, road no. 16, Huangshi, 435003, Hubei, China.
  • Lv C; Department of Urology, Haikou Municipal Hospital, Haikou, 570208, Hainan, China.
  • Shen C; Yixing Cancer Hospital, Dongshan Dong Lu No. 45, Yixing, 214200, Jiangsu, China.
  • Gong W; Yixing Cancer Hospital, Dongshan Dong Lu No. 45, Yixing, 214200, Jiangsu, China.
  • Wu J; Yixing Cancer Hospital, Dongshan Dong Lu No. 45, Yixing, 214200, Jiangsu, China.
  • Chen X; Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, Huangshi, 435000, Hubei, China.
  • Hu W; Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, Huangshi, 435000, Hubei, China.
  • Lv X; Yixing Cancer Hospital, Dongshan Dong Lu No. 45, Yixing, 214200, Jiangsu, China. 64705361@qq.com.
  • Si W; Hubei Key Laboratory for Kidney Disease Pathogenesis and Intervention, Hubei Polytechnic University School of Medicine, Xialu District guilin north, road no. 16, Huangshi, 435003, Hubei, China. 203133@hbpu.edu.cn.
  • Yu X; Hubei Key Laboratory for Kidney Disease Pathogenesis and Intervention, Hubei Polytechnic University School of Medicine, Xialu District guilin north, road no. 16, Huangshi, 435003, Hubei, China. yuxin@zqmc.cn.
Cancer Cell Int ; 21(1): 390, 2021 Jul 21.
Article em En | MEDLINE | ID: mdl-34289837
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Cancer Cell Int Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Cancer Cell Int Ano de publicação: 2021 Tipo de documento: Article